Mishra Vineet, Gandhi Khusaili, Roy Priyankur, Hokabaj Shaheen, Shah Kunur N
Department of Obstetrics and Gynecology, Institute for Kidney Disease and Research Centre, BJ Medical College, Asarwa, Ahemdabad, India.
J Nepal Health Res Counc. 2017 Sep 8;15(2):96-99. doi: 10.3126/jnhrc.v15i2.18158.
Iron deficiency is a common nutritional deficiency amongst women of childbearing age. Peri-partum iron deficiency anaemia is associated with significant maternal, foetal and infant morbidity. Current options for treatment include oral iron, which can be ineffective and poorly tolerated, and red blood cell transfusions, which carry an inherent risk and should be avoided. Ferric carboxymaltose is a modern treatment option. The study was designed to assess the safety and efficacy of intravenous ferric carboxymaltose for correction of iron deficiency anaemia in pregnant women.
A prospective study was conducted at Institute of Kidney Disease and Research Centre, Ahmedabad from January 2014 to December 2016. Antenatal women (108) with iron deficiency anaemia were the study subjects. Socio-demographic profile was recorded and anaemia was assessed based on recent haemoglobin reports. Iron deficiency was diagnosed on basis of serum ferritin value. Intravenous ferric carboxymaltose as per total correction dose (maximum 1500mg) was administered to all women; the improvement in haemoglobin levels were assessed after 3 weeks of total dose infusion.
Most of the women(n= 45, 41.7%), were in the age group of 27-30 years. Most of the women (n = 64, 59.3%) had moderate anaemia as per WHO guidelines. Mean haemoglobin levels significantly increased over a period of 3 weeks after Ferric carboxymaltose administrationand no serious life threatening adverse events were observed.
Intravenous ferric carboxymaltose was safe and effective in pregnent women with iron deficiency anaemia.
缺铁是育龄女性中常见的营养缺乏症。围产期缺铁性贫血与孕产妇、胎儿和婴儿的显著发病情况相关。目前的治疗选择包括口服铁剂，其可能无效且耐受性差，以及红细胞输血，这存在内在风险且应避免。羧基麦芽糖铁是一种现代治疗选择。本研究旨在评估静脉注射羧基麦芽糖铁纠正孕妇缺铁性贫血的安全性和有效性。
2014年1月至2016年12月在艾哈迈达巴德的肾病与研究中心进行了一项前瞻性研究。研究对象为108名缺铁性贫血的产前女性。记录社会人口学特征，并根据近期血红蛋白报告评估贫血情况。根据血清铁蛋白值诊断缺铁。对所有女性按照总纠正剂量（最大1500mg）静脉注射羧基麦芽糖铁；在总剂量输注3周后评估血红蛋白水平的改善情况。
大多数女性（n = 45，41.7%）年龄在27 - 30岁之间。根据世界卫生组织指南，大多数女性（n = 64，59.3%）患有中度贫血。静脉注射羧基麦芽糖铁后，血红蛋白水平在3周内显著升高，且未观察到严重的危及生命的不良事件。
静脉注射羧基麦芽糖铁对缺铁性贫血孕妇安全有效。
